Should we quantify insulin resistance in patients with renal disease? (Q36341789)

13 August 2017

1 reference

title

Should we quantify insulin resistance in patients with renal disease? (English)

1 reference

13 August 2017

1 reference

Yvonne Shen

1

1 reference

PubMed ID

16354245

13 August 2017

Philip W Peake

series ordinal

2

1 reference

PubMed ID

16354245

13 August 2017

John J Kelly

series ordinal

3

1 reference

13 August 2017

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

10

1 reference

13 August 2017

6

1 reference

13 August 2017

599-605

1 reference

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

A population-based study of the incidence and outcomes of diagnosed chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Prevalence of kidney damage in Australian adults: The AusDiab kidney study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Premature cardiovascular disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Chronic kidney disease predicts cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Prevalence of vascular risk factors and vascular disease in predialysis chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

How to measure insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

HOMA index to assess insulin resistance in renal failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance and executive dysfunction in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance and risk for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance and risk of chronic kidney disease in nondiabetic US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Overview: obesity: what does it have to do with kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Association between albuminuria and proteinuria in the general population: the AusDiab Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Selective aspects of the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Modulation of insulin action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Immunologic function and survival in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Pathophysiological implications of insulin resistance on vascular endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

The changes in serum leptin, body fat mass and insulin resistance after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

A novel serum protein similar to C1q, produced exclusively in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Adiponectin: a link between excess adiposity and associated comorbidities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Adipocyte metabolism and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Insulin resistance and associated metabolic abnormalities in muscle: effects of exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Treatment of insulin resistance in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Metabolic effects of moxonidine and other centrally acting antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1797.2005.00490.X

10.1111/J.1440-1797.2005.00490.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16354245